Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

PURPOSE: Abiraterone acetate is a prodrug of abiraterone, a selective inhibitor of CYP17, the enzyme catalyst for two essential steps in androgen biosynthesis. In castration-resistant prostate cancers (CRPCs), extragonadal androgen sources may sustain tumor growth despite a castrate environment. Thi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ryan, Charles J., Smith, Matthew R., Fong, Lawrence, Rosenberg, Jonathan E., Kantoff, Philip, Raynaud, Florence, Martins, Vanessa, Lee, Gloria, Kheoh, Thian, Kim, Jennifer, Molina, Arturo, Small, Eric J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2849769/
https://ncbi.nlm.nih.gov/pubmed/20159824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.1281
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados